Key Takeaway
CagriSema from Novo Nordisk represents the next evolution in weight management medication. This CagriSema Novo Nordisk resource covers the essential information you need to make informed decisions.
CagriSema from Novo Nordisk represents the next evolution in weight management medication. This CagriSema Novo Nordisk resource covers the essential information you need to make informed decisions. By combining semaglutide with a long-acting amylin analog called cagrilintide, this dual-mechanism drug has produced some of the highest weight loss numbers seen in clinical trials. If you have been following the GLP-1 space, CagriSema is one of the names you should know.
Key Takeaways: - Understand what is cagrisema and how does it work - Clinical Trial Results: Up to 25% Weight Loss - Expected Timeline and Availability - CagriSema vs. Other Dual-Mechanism Drugs
Here is what the science says and when you might be able to access it.
What Is CagriSema and How Does It Work?
CagriSema is a fixed-ratio combination of two medications in a single weekly injection. The first component is semaglutide, the well-known GLP-1 receptor agonist. The second is cagrilintide, a long-acting analog of amylin.
You are probably familiar with how semaglutide works. It activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve blood sugar control. For a full breakdown, see our .
Amylin is the newer piece of the puzzle. It is a hormone that your pancreas releases alongside insulin after you eat. Amylin slows stomach emptying, reduces glucagon secretion (which lowers blood sugar spikes), and activates brain pathways involved in satiety. It works through different receptors than GLP-1, meaning the two hormones provide complementary appetite suppression through separate mechanisms.
Think of it this way: GLP-1 turns down your hunger through one set of brain signals. Amylin turns down your hunger through a different set. When you combine both, you get stronger appetite suppression than either one alone.
"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.") Dr. Caroline Apovian, MD, Harvard Medical School
Pramlintide (Symlin) is an existing amylin analog used for diabetes. But it requires multiple daily injections and has limitations. Cagrilintide is a long-acting version designed for once-weekly dosing, making it practical to combine with weekly semaglutide.
Clinical Trial Results: Up to 25% Weight Loss
The Phase 3 trial results for CagriSema have been impressive. The REDEFINE program studied CagriSema across multiple patient populations.
Free Download: GLP-1 Medication Comparison One-Pager See how CagriSema's weight loss data compares to semaglutide, tirzepatide, and other options. Get yours free (we'll email it to you instantly. [Email Input] [Download Button]
In the REDEFINE 1 trial, participants taking CagriSema lost approximately 22-25% of their body weight over 68 weeks. This puts CagriSema near the top of all weight management medications studied to date.
CagriSema also showed superiority over semaglutide alone. In head-to-head comparisons, the combination produced significantly more weight loss than the same dose of semaglutide by itself. This confirms that adding amylin provides a meaningful additional benefit.
The side effect profile was similar to other GLP-1 medications. Nausea, vomiting, and diarrhea were the most commonly reported adverse events. Rates were generally comparable to semaglutide alone, suggesting that adding cagrilintide does not dramatically increase gastrointestinal side effects.
Blood sugar improvements were also strong. CagriSema significantly reduced A1C in participants with type 2 diabetes, performing better than semaglutide alone.
For context on how these numbers compare to tirzepatide, read our .
Expected Timeline and Availability
Novo Nordisk has submitted regulatory filings for CagriSema based on the Phase 3 data. The FDA and European regulatory agencies are reviewing the applications.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Based on typical regulatory timelines, CagriSema could receive approval in late 2026 or early 2027. However, approval does not guarantee immediate broad availability. Manufacturing scale-up, insurance negotiations, and distribution logistics all take time.
Pricing has not been officially announced. Given that CagriSema combines two active ingredients and is a premium product from Novo Nordisk, it will likely be priced at a premium compared to semaglutide alone.
If you are looking for effective treatment available today, FormBlends offers personalized compounded GLP-1 medications prescribed by licensed providers and prepared by US-based 503A pharmacies. You do not need to wait for CagriSema to start working toward your health goals.
CagriSema vs. Other Dual-Mechanism Drugs
CagriSema is not the only dual-mechanism drug in development. Knowing how it compares helps you see the market.
CagriSema (GLP-1 + amylin) uses two appetite-suppressing hormones through different brain pathways. Weight loss in trials: approximately 22-25%.
Tirzepatide (GLP-1 + GIP) targets GLP-1 and GIP receptors to improve metabolic function and reduce appetite. Weight loss in trials: approximately 22%. It is already FDA-approved and available.
Survodutide (GLP-1 + glucagon) adds glucagon receptor activation to increase energy expenditure and promote liver fat breakdown. Phase 2 weight loss: approximately 19%. Still in Phase 3 trials.
Retatrutide (GLP-1 + GIP + glucagon) is the only triple agonist in development. Phase 2 weight loss: approximately 24%. Still in Phase 3 trials.
Each approach has unique advantages. CagriSema's amylin component specifically targets satiety pathways. Glucagon-containing drugs like survodutide may be better for liver health. Your provider can help you evaluate which mechanism best fits your health profile.
For a full comparison, visit our .
Frequently Asked Questions
What is cagrilintide?
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone released by the pancreas that suppresses appetite, slows gastric emptying, and reduces blood sugar spikes. Cagrilintide is designed for once-weekly injection, making it practical to combine with semaglutide.
How much weight can you lose on CagriSema?
Phase 3 trials showed weight loss of approximately 22-25% of body weight over 68 weeks. This is among the highest weight loss numbers reported for any medication in clinical trials. Individual results vary based on diet, exercise, and other factors.
When will CagriSema be available?
CagriSema is currently under regulatory review. If approved, it could be available in late 2026 or early 2027. Manufacturing and insurance coverage timelines will affect broad availability.
Is CagriSema better than semaglutide alone?
In clinical trials, CagriSema produced significantly more weight loss than semaglutide alone. The addition of cagrilintide provides complementary appetite suppression through amylin pathways. However, it is a new medication without the same long-term safety data as semaglutide, which has been studied extensively for years.
Can I get CagriSema through FormBlends?
CagriSema is not yet available through any provider, as it has not received FDA approval. FormBlends currently offers effective compounded GLP-1 medications with licensed providers.
What's Your Next Move?
You have the information. Now let a licensed provider help you put it into action. FormBlends makes it simple, answer a few questions and get a personalized recommendation.
Sources & References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
This content is provided for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed healthcare provider with any questions about a medical condition or treatment plan.
Last updated: 2026-03-24